Aligos Therapeutics, Inc. announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). Dr. Blatt will provide a corporate update and discuss the company's entire pipeline, including ALG-055009, the coronavirus protease inhibitor ALG-097558, and Aligos' hepatitis B portfolio, on January 12, 2023, at 10:30 a.m. PT during the 41st Annual JP Morgan Healthcare Conference in San Francisco. Dr. Blatt's presentation will also be posted on the Aligos website at the time of the conference.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.665 USD | +4.15% | -0.90% | +1.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.36% | 49.87M | |
+61.49% | 55.07B | |
-1.89% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.77% | 26.28B | |
-21.01% | 18.93B | |
+6.95% | 13.03B | |
+28.20% | 12.26B | |
+26.42% | 12.21B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009